News
We send the latest information from SMC Laboratories.
kk
We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis (NASH) model called STAMTM (Ikewaki et al., bioRxiv, 2021). In this study, the authors evaluated how the single or combined consumption of two beta-glucans derived from the AFO-202 and N-163 strains of black yeast, Aureobasidium pullulans, affected the…
Introduction of the paper using our UUO model
We would like to introduce a paper published by our client using Chronic kidney disease model. In this paper, the authors showed improvement of the disease state and analyzed the mechanism of UUO-induced kidney fibrosis model by histological analysis and gene expression analysis after the administration of compounds. About the UUO…
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunction-associated fatty liver disease is a new concept in the understanding of fatty liver disease and it’s pathogenesis. A consensus statement on this disease concept was published in the Journal of Hepatology in 2020. For…
Drug efficacy studies using multiple mouse models to replicate human disease.
To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of NASH. However, no therapeutic medications for NASH have yet been launched. One of the reasons is the lack of animal models that can completely reproduce the pathology of NASH as seen in humans due to the…
The comparison of NASH-HCC and other HCC models
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020. Among them, hepatocellular carcinoma (HCC) is known to account for about 90% of all liver cancers. Hepatitis B and C, alcohol, and diabetes are known to cause HCC, but NAFLD/NASH has been…
Marvel Biosciences has published a press release regarding the MB-207 efficacy evaluation study for liver fibrosis provided by SMC
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ mouse model. For detail information, see the Marvel's press release. Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash | MARVEL Biotechnology
STZ: Type 1 or Type 2 Diabetes?
When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does the streptozotocin induce? Since streptozotocin (an N-acetyl-β-D-glucosaminidase inhibitor; STZ) is cytotoxic to pancreatic beta cells, STZ-induced diabetes models are often considered as a model for Type 1 diabetes mellitus (T1D) which is in definition caused…
Lung fibrosis in COVID-19
COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damage to other organs such as the liver, kidney and intestines. Recent reports have focused on lung fibrosis. COVID-19 develops via infection with a virus belonging to the beta-coronavirus class, similar to the virus that…
ENYO Pharma announces positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks
ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks. For detailed information, see the URL below. https://www.businesswire.com/news/home/20210728005557/en/ENYO-Pharma-Announces-Positive-Vonafexor-EYP001-Results-for-the-LIVIFY-Phase-2a-Study-in-F2-F3-NASH-Patients-over-12-weeks Vonafexor is a synthetic non-steroidal, non-Bile Acid, highly selective FXR agonist. This is used the STAM™ mouse model for non-clinical…
New Partnership with cancer model search service Repositive, Inc.
SMC Laboratories, Inc. is pleased to announce a partnership with Repositive, Inc., a UK-based bespoke cancer model search service. Repositive supports researchers working in oncology to find the right cancer models for their studies. They also organise and curate cancer model data from partner CROs, and present this inventory of models online, via their beta…